SEOM‑GEMCAD‑TTD clinical guidelines for the management of hepatocarcinoma patients (2023)

• Carlos López López ^[6] ; Mariona Calvo ^[7] ; Juan Carlos Cámara ^[1] ; Beatriz García Paredes ^[2] ; Javier Sastre ^[2] ; Carlos Gómez Martin ^[3] ; Ana María López ^[4] ; Roberto Pazo Cid ^[5] ; Ricardo Yaya ^[8] ; Jaime Feliu ^[9]
  1. [1] Fundación Hospital Alcorcón

     Fundación Hospital Alcorcón

     Alcorcón, España

     
  2. [2] Hospital Clínico San Carlos de Madrid

     Hospital Clínico San Carlos de Madrid

     Madrid, España

     
  3. [3] Hospital Universitario 12 de Octubre

     Hospital Universitario 12 de Octubre

     Madrid, España

     
  4. [4] Complejo Asistencial Universitario de Burgos

     Complejo Asistencial Universitario de Burgos

     Burgos, España

     
  5. [5] Hospital Miguel Servet

     Hospital Miguel Servet

     Zaragoza, España

     
  6. [6] Medical Oncology Department, H. U. Marqués de Valdecilla, IDIVAL, UNICAN, Santander, Cantabria, Spain
  7. [7] Medical Oncology Department, Institut Català d’Oncologia-L’Hospitalet del Llobregat, Barcelona, Spain
  8. [8] Medical Oncology Department, Instituvo Valenciano de Oncología, Valencia, Spain
  9. [9] Medical Oncology Department, Hospital Universitario de La Paz, IdiPAZ, CIBERONC, UAM, Madrid, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 26, Nº. 11, 2024, págs. 2800-2811
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Hepatocellular carcinoma (HCC) is the most common primary malignancy in the liver and is the third cause of cancer-related death worldwide. Surveillance with abdominal ultrasound should be ofered to individuals at high risk for developing HCC. Accurate diagnosis, staging, and liver function are crucial when determining the optimal therapeutic approach. The BCLC staging system is widely endorsed in Western countries. Managing this pathology requires a multidisciplinary, personalized approach, generally with a multimodal strategy. Surgery remains the only curative option, albeit local and systemic therapy may also increase survival when surgery is not suitable. In advanced disease, systemic treatment should be ofered to patients with ECOG/PS 0-1 and Child–Pugh class A.